Generation of T cell effectors using tumor cell-loaded dendritic cells for adoptive T cell therapy
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články
PubMed
27812850
DOI
10.1007/s12032-016-0855-4
PII: 10.1007/s12032-016-0855-4
Knihovny.cz E-zdroje
- Klíčová slova
- Adoptive T cell therapy, Cancer immunotherapy, Prostate cancer, Tumor-specific T cell expansion,
- MeSH
- aktivace lymfocytů MeSH
- antigeny nádorové imunologie MeSH
- bioreaktory MeSH
- dendritické buňky imunologie MeSH
- epitopy T-lymfocytární imunologie MeSH
- imunoterapie adoptivní metody MeSH
- interferon gama biosyntéza imunologie MeSH
- lidé MeSH
- nádorové buněčné linie MeSH
- nádory prostaty imunologie MeSH
- nádory vaječníků imunologie MeSH
- regulační T-lymfocyty imunologie MeSH
- studie případů a kontrol MeSH
- T-lymfocyty - podskupiny imunologie MeSH
- T-lymfocyty imunologie MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- antigeny nádorové MeSH
- epitopy T-lymfocytární MeSH
- interferon gama MeSH
Adoptive T cell transfer has been shown to be an effective method used to boost tumor-specific immune responses in several types of malignancies. In this study, we set out to optimize the ACT protocol for the experimental treatment of prostate cancer. The protocol includes a pre-stimulation step whereby T cells were primed with autologous dendritic cells loaded with the high hydrostatic pressure-treated prostate cancer cell line, LNCaP. Primed T cells were further expanded in vitro with anti-CD3/CD28 Dynabeads in the WAVE bioreactor 2/10 system and tested for cytotoxicity. Our data indicates that the combination of pre-stimulation and expansion steps resulted in the induction and enrichment of tumor-responsive CD4+ and CD8+ T cells at clinically relevant numbers. The majority of both CD4+ and CD8+ IFN-γ producing cells were CD62L, CCR7 and CD57 negative but CD28 and CD27 positive, indicating an early antigen experienced phenotype in non-terminal differentiation phase. Expanded T cells showed significantly greater cytotoxicity against LNCaP cells compared to the control SKOV-3, an ovarian cancer line. In summary, our results suggest that the ACT approach together with LNCaP-loaded dendritic cells provides a viable way to generate prostate cancer reactive T cell effectors that are capable of mounting efficient and targeted antitumor responses and can be thus considered for further testing in a clinical setting.
Department of Pediatric and Adult Rheumatology Faculty Hospital Motol Prague Czech Republic
Laboratory of Immunobiology Institute of Molecular Genetics of the AS CR Prague Czech Republic
Zobrazit více v PubMed
J Exp Med. 2005 Oct 3;202(7):907-12 PubMed
J Transl Med. 2012 Aug 21;10:169 PubMed
J Transl Med. 2012 Apr 04;10:69 PubMed
J Immunol. 2006 Nov 1;177(9):6527-39 PubMed
Clin Cancer Res. 2012 Dec 15;18(24):6758-70 PubMed
Curr Opin Immunol. 2014 Apr;27:1-7 PubMed
Curr Opin Investig Drugs. 2007 Dec;8(12):1002-8 PubMed
J Immunother. 2005 May-Jun;28(3):258-67 PubMed
Clin Cancer Res. 2010 May 1;16(9):2646-55 PubMed
Oncoimmunology. 2016 Jul 01;5(8):e1202391 PubMed
J Immunol Methods. 2010 Apr 15;355(1-2):52-60 PubMed
Clin Cancer Res. 2011 Jul 1;17(13):4550-7 PubMed
J Immunol Methods. 1987 Aug 24;102(1):127-41 PubMed
Cancer Res. 2010 Nov 1;70(21):8378-87 PubMed
J Immunol Methods. 2003 Apr 1;275(1-2):251-5 PubMed
Int J Oncol. 2016 Mar;48(3):953-64 PubMed
J Biomed Biotechnol. 2010;2010:956304 PubMed
Cancer Res. 2011 May 15;71(10 ):3540-51 PubMed
J Immunol. 2001 Aug 1;167(3):1712-9 PubMed
Int J Cancer. 2014 Sep 1;135(5):1165-77 PubMed
Blood. 2005 Jan 1;105(1):241-50 PubMed
Nat Rev Cancer. 2012 Mar 22;12(4):252-64 PubMed
Prostate. 2007 Mar 1;67(4):389-95 PubMed
J Immunother. 2003 Jul-Aug;26(4):332-42 PubMed
J Immunol. 2005 Mar 1;174(5):2591-601 PubMed
J Urol. 1997 Sep;158(3 Pt 1):740-5 PubMed
Annu Rev Immunol. 2014;32:189-225 PubMed
J Immunol. 1984 Oct;133(4):1710-5 PubMed
Blood. 2007 Aug 15;110(4):1123-31 PubMed
CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29 PubMed
Science. 2002 Oct 25;298(5594):850-4 PubMed
Int J Cancer. 2010 Aug 15;127(4):748-58 PubMed
Eur J Cancer. 2016 Jan;52:50-66 PubMed
Oncoimmunology. 2015 Jan 7;3(12):e968434 PubMed
Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2:14639-45 PubMed
J Transl Med. 2010 Oct 26;8:104 PubMed
Science. 2015 Apr 3;348(6230):69-74 PubMed
Int J Cancer. 2010 Apr 1;126(7):1582-95 PubMed
Immunol Lett. 2014 Jul;160(1):39-49 PubMed
Hum Vaccin Immunother. 2015;11(12):2790-5 PubMed
Nat Immunol. 2000 Nov;1(5):433-40 PubMed
Clin Cancer Res. 2016 Aug 1;22(15):3734-45 PubMed
Cancer Immunol Immunother. 2003 Jul;52(7):445-54 PubMed
Clin Cancer Res. 2007 Mar 15;13(6):1883-91 PubMed
